REG - Futura Medical PLC - Notice of Results & Investor Presentation

Futura MedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260420:nRST0911Ba&default-theme=true

RNS Number : 0911B  Futura Medical PLC  20 April 2026

 20 April 2026

 

Futura Medical plc

("Futura" or the "Company")

Notice of Results & Investor Presentation

 

Futura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon®
and that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, will release its full
year results for the year ended 31 December 2025 on Wednesday 29 April.

Management will be hosting a webinar relating to the results via the Investor
Meet Company platform on Wednesday 29 at 10:00 BST.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via the Investor Meet Company dashboard up until
9.00am BST the day before, or at any time during the live presentation.

Investors can register for the presentation via the following
link: https://www.investormeetcompany.com/futura-medical-plc/register-investor
(https://www.investormeetcompany.com/futura-medical-plc/register-investor)
. Investors who already follow Futura on the Investor Meet Company platform
will automatically be invited.

 

Contacts:

 Futura Medical plc                 Alexander Duggan                                        investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                    Chief Executive Officer

                                                       +44 (0)1483 685 670
                                    Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                    Finance Director and COO

 Panmure Liberum                    Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser

 and Broker

 Turner Pope Investments (TPI) Ltd  Guy McDougall, Andrew Thacker                           +44 (0) 20 3657 0050

 Broker

 Alma Strategic Communications      Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters        +44 (0)20 3405 0205

                                                                                            futura@almastrategic.com (mailto:futura@almastrategic.com)

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon® and development products WSD4000 and
Eroxon® Intense. Our core strength lies in the research, development and
commercialisation of topically delivered gel formulations in sexual health
products.

Sexual health issues are prevalent in both men and women. Erectile Dysfunction
("ED") impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. Around 60% of women experience at least one
symptom of sexual dysfunction, and only one in four women seek professional
help, and remain chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the
treatment of ED. The highly differentiated product, which is the only topical
gel treatment for ED available over the counter and helps men get an erection
in ten minutes, addresses significant unmet needs in the ED market. Eroxon®
has been nominated for a number of healthcare industry awards and has won two
to-date.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

WSD4000 is a topical treatment designed for the symptoms of impaired sexual
response and function in women. There is currently no regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal and lubrication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREAELNFEXKEAA



            Copyright 2019 Regulatory News Service, all rights reserved